Who are IM epinephrine 1:1000's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ephedrine, bolus, Epinephrin 0.01, High-dose epinephrine, Ephedrine-S, cardiac output changes with "ephedrine", Low-dose epinephrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/im-epinephrine-1-1000.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

IM epinephrine 1:1000 — Competitive Intelligence Brief

IM epinephrine 1:1000 (IM epinephrine 1:1000) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Catecholamine; adrenergic agonist. Area: Emergency Medicine; Allergy/Immunology.

marketed Catecholamine; adrenergic agonist Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors Emergency Medicine; Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

IM epinephrine 1:1000 (IM epinephrine 1:1000) — University of Louisville. Epinephrine is a catecholamine that activates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and bronchial dilation while suppressing immune mediator release.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IM epinephrine 1:1000 TARGET	IM epinephrine 1:1000	University of Louisville	marketed	Catecholamine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Ephedrine, bolus	Ephedrine, bolus	University of Parma	marketed	Sympathomimetic amine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Epinephrin 0.01	Epinephrin 0.01	Kasr El Aini Hospital	marketed	Catecholamine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
High-dose epinephrine	High-dose epinephrine	Icahn School of Medicine at Mount Sinai	marketed	Catecholamine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Ephedrine-S	Ephedrine-S	Dalian Municipal Central Hospital	marketed	Sympathomimetic amine	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
cardiac output changes with "ephedrine"	cardiac output changes with "ephedrine"	University Tunis El Manar	marketed	Sympathomimetic amine	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Low-dose epinephrine	Low-dose epinephrine	Icahn School of Medicine at Mount Sinai	marketed	Sympathomimetic amine / Catecholamine	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Catecholamine; adrenergic agonist class)

Kasr El Aini Hospital · 2 drugs in this class
Aga Khan University · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
Ministry of Health, Spain · 1 drug in this class
University of Louisville · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IM epinephrine 1:1000 — Competitive Intelligence Brief. https://druglandscape.com/ci/im-epinephrine-1-1000. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab